Seroprevalence of SARS-CoV-2 among high-risk healthcare workers in a MERS-CoV endemic area

Journal of Infection and Public Health

Emad Masuadi¹  Modhi Aljedaie²  Lulwah Alabdan²  Amre Nasr²  Naif Khalaf Alharbi³  Yaseen M. Arabi⁴  Maysa Nogoud⁴  Fayhan Alroqi⁵  Abdulrahman Alsaedi⁶  Tlili Barhoumi⁶  Abdulrahman Almasoud⁶  Mohammad Khan⁶  Ahmad S. Abu-Jaffal⁷ 

[1] College of Medicine, King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), Riyadh, Saudi Arabia;King Abdullah International Medical Research Centre (KAIMRC), Ministry of National Guard Health Affairs (MNGHA), Riyadh, Saudi Arabia;College of Applied Medical Sciences, King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), Riyadh, Saudi Arabia;College of Medicine, King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), Riyadh, Saudi Arabia;Department of Paediatric, King Abdullah Specialized Children’s Hospital (KASCH), Ministry of the National Guard - Health Affairs, City, Saudi Arabia;King Abdullah International Medical Research Centre (KAIMRC), Ministry of National Guard Health Affairs (MNGHA), Riyadh, Saudi Arabia;Prince Mohammed Bin Abdul Aziz Hospital (PMAH), Ministry of Health, Riyadh, Saudi Arabia;

关键词: COVID-19;    Seroprevalence;    SARS-CoV-2;    IgG antibody;    Healthcare workers;   

DOI  :  

来源: DOAJ

【 摘 要 】

Introduction: Healthcare workers (HCWs) in Saudi Arabia are a unique population who have had exposures to the Middle East Respiratory Syndrome coronavirus (MERS-CoV) and Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). It follows that HCWs from this country could have pre-existingMERS-CoV antibodies that may either protect from coronavirus disease 2019 (COVID-19) infection or cause false SARS-CoV-2 seropositive results. In this article, we report the seroprevalence of MERS-CoV and SARS-CoV-2 among high-risk healthcare workers in Riyadh city, Saudi Arabia. Methods: This is a cross-sectional study enrolling 420 high-risk HCWs who are physically in contact with COVID-19 patients in three tertiary hospitals in Riyadh city. The participants were recruited between the 1st of July to the end of December 2020. A 3 ml of the venous blood samples were collected and tested for the presence of IgG antibodies against the spike proteins of SARS-CoV-2 and MERS-CoV using enzyme-linked immunosorbent assay (ELISA). Results: The overall prevalence of SARS-CoV-2 in high-risk HCWs was 14.8% based on SARS-CoV-2 IgG testing while only 7.4% were positive by Polymerase Chain Reaction (PCR) for viral RNA. Most of the SARS-CoV-2 seropositive HCWs had symptoms and the most frequent symptoms were body aches, fever, cough, loss of smell and taste, and headache. The seroprevalence of MERS-CoV IgG was 1% (4 participants) and only one participant had dual seropositivity against MERS-CoV and SARS-CoV-2. Three MERS-CoV positive samples (75%) turned to be negative after using in-house ELISA and none of the MERS-CoV seropositive samples had detectable neutralization activity. Conclusion: Our SARS-CoV-2 seroprevalence results were higher than reported regional seroprevalence studies. This finding was expected and similar to other international findings that targeted high-risk HCWs. Our results provide evidence that the SARS-CoV-2- seropositivity in Saudi Arabia similar to other countries was due to exposure to SARS-CoV-2 rather than MERS-CoV antibody.

【 授权许可】

Unknown